Acute pancreatitis is an acute inflammatory condition of the pancreas and a common cause of gastrointestinal hospitalization. It is diagnosed clinically using the revised Atlanta criteria, typically combining abdominal pain with elevated pancreatic enzymes and/or characteristic imaging findings.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07464392 |
FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis |
RECRUITING | NA |
| NCT07375186 |
Early Oral Carbohydrate Solution vs Clear Liquid Diet in Acute Pancreatitis |
NOT_YET_RECRUITING | NA |
| NCT07322978 |
Incidence of Splanchnic Venous Thrombosis in Acute Pancreatitis and it's Correlation With Severity of Pancreatitis |
RECRUITING | |
| NCT07153809 |
Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis |
RECRUITING | NA |
| NCT07084428 |
Pancreatic Antibiotic Concentration Evaluation Assessment |
ACTIVE_NOT_RECRUITING | |
| NCT06899087 |
DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis |
RECRUITING | |
| NCT06639516 |
Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial |
NOT_YET_RECRUITING | NA |
| NCT06600828 |
Study's Care of Acute Pancreatitis at Saint-Etienne University Hospital. |
RECRUITING | |
| NCT06566638 |
Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA/NETs in Subjects With Pancreatitis |
NOT_YET_RECRUITING | NA |
| NCT06553651 |
Necrosectomy With Cryotechnology for Accelerated Removal |
RECRUITING | NA |
